Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer
November 7th 2012Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.
Switching Therapy Following Suboptimal Response in Chronic Myelogenous Leukemia
November 7th 2012Now that several effective agents are FDA-approved for the treatment of CML, it is important to ascertain whether a treatment is working, and if not, how to respond in terms of switching treatment.
No Survival Benefit Found When Adding Bevacizumab to Gemcitabine/Cisplatin in Malignant Mesothelioma
October 31st 2012The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.
Extending Adjuvant Chemotherapy Offers No Additional Benefit in Low-Risk Primary Breast Cancer
October 29th 2012Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.
A Multivitamin Each Day Keeps Cancer Away
October 23rd 2012New data from a study sponsored by the National Institutes of Health appear to have proven that there is an inexpensive and relatively simple approach to reducing the incidence of most cancers that afflict men: Take a multivitamin daily.